Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Genmab A/S

< Previous 1 2 Next >
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
Tickers GMAB
TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
From Genmab A/S
Via GlobeNewswire
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
From Genmab A/S
Via GlobeNewswire
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Publishes 2024 Annual Report
From Genmab A/S
Via GlobeNewswire
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024
From Genmab A/S
Via GlobeNewswire
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
From Genmab A/S
Via Business Wire
Tickers GMAB
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
From Genmab A/S
Via Business Wire
Tickers GMAB
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Financial Results for the First Nine Months of 2024
From Genmab A/S
Via GlobeNewswire
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
From Genmab A/S
Via GlobeNewswire
Major Shareholder Announcement
From Genmab A/S
Via GlobeNewswire
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
From Genmab A/S
Via Business Wire
Tickers GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via GlobeNewswire
Genmab Announces Changes to its Executive Committee
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Announces Financial Results for the First Half of 2024
From Genmab A/S
Via GlobeNewswire
Genmab Updates 2024 Financial Guidance
From Genmab A/S
Via GlobeNewswire
Genmab Takes Full Control of Acasunlimab Development Program
From Genmab A/S
Via GlobeNewswire
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
From Genmab A/S
Via GlobeNewswire
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
Tickers GMAB
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
From Genmab A/S
Via Business Wire
Tickers GMAB
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
From Genmab A/S
Via Business Wire
Tickers GMAB
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
From Genmab A/S
Via Business Wire
Tickers BNTX GMAB
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Genmab A/S
Via Business Wire
Tickers GMAB
Genmab Completes Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
Tickers GMAB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS